Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250718 · ClinicalTrials.gov registry record · Phase 2
Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00250718: Clinical Trial Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
NCT00250718 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00250718, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dose administration of chemotherapy on angiogenesis, and correlate this with tumor responses.
Primary Outcome
Solid tumor response is per Response Evaluation Criteria in Solid Tumors (RECIST) (ver 1.0). For CLL: complete remission (CR) requires the following for\>=2 months 1) no symptoms attributable to CLL, 2) normal physical examination, 3) absolute lymphocyte count\<4,000/µL, 4) ANC\>1,500/µL, 5) platelets\>100,000/µL, 6) hemoglobin\>11 g/dL, 7) bone marrow lymphocytosis\<30%, 8) no nodules in bone marrow. Partial response (PR) requires the following for \>=2 months 1) decrease in previously enlarge
Interventions
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Levofloxacin
- DRUG VP-16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Why NCT00250718 stopped before completion
NCT00250718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Rituximab is the first listed.
NCT00250718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00250718 about?
NCT00250718 is a clinical study titled "Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach". 1.1 To determine the efficacy of a combination treatment of VP-16, chlorambucil, dexamethasone, and vincristine in patients with relapsed/refractory hematological malignancies. 1.2 To determine the toxicity profile of the above regimen in this patient population. 1.3 Evaluate the effect of low dos...
What is the current status of trial NCT00250718?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT00250718?
The interventions under investigation include: Rituximab (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Levofloxacin (DRUG), VP-16 (DRUG).
Who is sponsoring clinical trial NCT00250718?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00250718's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia